Celecoxib versus Diclofenac and Omeprazole in Reducing the Risk of Recurrent Ulcer Bleeding in Patients with Arthritis

This randomized, controlled trial compared treatment with celecoxib and treatment with diclofenac plus omeprazole in patients with arthritis and ulcer bleeding. The rates of recurrent ulcer bleeding during six months of follow-up were similar in the two groups (4.9 percent in the celecoxib group and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2002-12, Vol.347 (26), p.2104-2110
Hauptverfasser:	Chan, Francis K.L, Hung, Lawrence C.T, Suen, Bing Y, Wu, Justin C.Y, Lee, Kenneth C, Leung, Vincent K.S, Leung, Wai K, Hui, Aric J, To, Ka F, Wong, Vincent W.S, Chung, S.C. Sydney, Sung, Joseph J.Y
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-Inflammatory Agents, Non-Steroidal - adverse effects Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Anti-Ulcer Agents - therapeutic use Arthritis - drug therapy Biological and medical sciences Celecoxib Cyclooxygenase 2 Cyclooxygenase 2 Inhibitors Cyclooxygenase Inhibitors - adverse effects Cyclooxygenase Inhibitors - therapeutic use Diclofenac - adverse effects Diclofenac - therapeutic use Digestive system Double-Blind Method Drug dosages Drug therapy Drug Therapy, Combination Duodenal Ulcer - chemically induced Duodenal Ulcer - prevention & control Helicobacter pylori - isolation & purification Humans Isoenzymes - antagonists & inhibitors Medical sciences Membrane Proteins Omeprazole - therapeutic use Peptic Ulcer Hemorrhage - chemically induced Peptic Ulcer Hemorrhage - prevention & control Pharmacology. Drug treatments Probability Prospective Studies Prostaglandin-Endoperoxide Synthases Pyrazoles Risk Factors Secondary Prevention Stomach Ulcer - chemically induced Stomach Ulcer - prevention & control Sulfonamides - adverse effects Sulfonamides - therapeutic use Ulcers
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!